Market Overview:
The global adenosine deaminase deficiency drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of adenosine deaminase deficiency, rising awareness about adenosine deaminase deficiency drugs, and technological advancements in the field of drug development. Based on type, the global adenosine deaminase deficiency drugs market is segmented into Adagen and Revcovi. Adagen is currently available as a treatment for patients with severe combined immunodeficiency (SCID) due to ADA-deficiency. Revcovi is an enzyme replacement therapy that has been approved by the US Food and Drug Administration (FDA) for use in patients with ADA-deficient SCID who are greater than 6 months old and have not had successful treatment with bone marrow transplantation or gene therapy. Based on application, the global adenosine deaminase deficiency drugs market is segmented into hospital pharmacies and retail pharmacies. Hospital pharmacies are expected to account for a larger share of this market than retail pharmacies during the forecast period owing to their larger customer base and higher spending power among patients suffering from ADA-deficient diseases.
Product Definition:
Adenosine deaminase deficiency drugs are used to treat people with a rare genetic disorder that affects the ability to fight infections. The disorder is called adenosine deaminase deficiency, and it affects about 1 in every 200,000 people in the United States. People with this disorder cannot make an enzyme called adenosine deaminase (ADA). This enzyme is important for breaking down a chemical called adenosine. When ADA is not working properly, too much adenosine builds up in the body. This can damage cells and lead to serious health problems. Adenosine deaminase deficiency drugs help replace the missing enzyme so that the body can break down adenosine properly.
Adagen:
Adagen is a prescription medicine used for the treatment of hereditary adenosine deaminase (ADA) deficiency. The condition is caused by an abnormal gene that leads to reduced production of ADA in the body. This enzyme plays an important role in removing waste from cells and controlling blood sugar levels.
The main symptoms associated with this disease are severe fatigue, frequent infections, low blood pressure, frequent urination, and diabetes type II ( maturity-onset diabetes).
Revcovi:
The drug is a form of vitamin C which helps in the treatment and prevention of several diseases such as scurvy, bleeding disorders, and arthritis. Vitamin C also aids in the healing process of different types of wounds including surgical incisions. The drug was developed by Lederle Laboratories for treating adenosine deaminase deficiency (ADA).
Application Insights:
The global ADAD deficiency drugs market is segmented on the basis of application into hospital, pharmacy and others. The hospital segment dominated the overall market in terms of revenue share in 2017. This can be attributed to a high prevalence of ADAD deficiency across various regions coupled with increasing healthcare spending due to an aging population.
In addition, factors such as growing awareness about adenosine deaminase deficiency among individuals who are at risk for developing symptoms associated with the disease and availability of effective treatment options are also contributing towards higher usage rates in hospitals across various regions globally. Hospital application accounts for a larger share owing to its ability to treat more number of patients at once which results in reduced cost per patient treated compared to other applications such as pharmacies or clinical settings.
Regional Analysis:
North America dominated the global ADase deficiency drugs market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of target diseases are some factors attributing to this dominance. In addition, growing healthcare awareness levels coupled with the availability of novel therapies for ADase deficient patients is expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income levels and improving healthcare infrastructure in emerging countries such as China & India. Furthermore, an increase in diabetes-related disorders coupled with a rise in cardiovascular diseases (CVDs) is also expected fuel regional demand during the same period.
Growth Factors:
- Increasing prevalence of adenosine deaminase deficiency (ADA)
- Growing demand for novel and targeted therapies for ADA
- Rising awareness about ADA and its treatment options
- Technological advancements in the field of adenosine deaminase therapy
- Availability of government funding for research on ADA
Scope Of The Report
Report Attributes
Report Details
Report Title
Adenosine Deaminase Deficiency Drugs Market Research Report
By Type
Adagen, Revcovi
By Application
Hospital, Pharmacy
By Companies
Leadiant Biosciences, Leadiant Biosciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
165
Number of Tables & Figures
116
Customization Available
Yes, the report can be customized as per your need.
Global Adenosine Deaminase Deficiency Drugs Market Report Segments:
The global Adenosine Deaminase Deficiency Drugs market is segmented on the basis of:
Types
Adagen, Revcovi
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Leadiant Biosciences
- Leadiant Biosciences
Highlights of The Adenosine Deaminase Deficiency Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Adagen
- Revcovi
- By Application:
- Hospital
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Adenosine Deaminase Deficiency Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Adenosine deaminase deficiency drugs are medications used to treat a condition caused by a lack of adenosine deaminase enzyme. ADEs can be life-threatening if not treated quickly.
Some of the key players operating in the adenosine deaminase deficiency drugs market are Leadiant Biosciences, Leadiant Biosciences.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Adenosine Deaminase Deficiency Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Adenosine Deaminase Deficiency Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Adenosine Deaminase Deficiency Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Adenosine Deaminase Deficiency Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Adenosine Deaminase Deficiency Drugs Market Size & Forecast, 2020-2028
4.5.1 Adenosine Deaminase Deficiency Drugs Market Size and Y-o-Y Growth
4.5.2 Adenosine Deaminase Deficiency Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Adagen
5.2.2 Revcovi
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Adenosine Deaminase Deficiency Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Adenosine Deaminase Deficiency Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Adagen
9.6.2 Revcovi
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Adagen
10.6.2 Revcovi
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Adagen
11.6.2 Revcovi
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Adagen
12.6.2 Revcovi
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Adagen
13.6.2 Revcovi
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Adenosine Deaminase Deficiency Drugs Market: Competitive Dashboard
14.2 Global Adenosine Deaminase Deficiency Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Leadiant Biosciences
14.3.2 Leadiant Biosciences
